<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04723914</url>
  </required_header>
  <id_info>
    <org_study_id>HEM-ONCO-006</org_study_id>
    <nct_id>NCT04723914</nct_id>
  </id_info>
  <brief_title>Dual Target CAR-T Cells in B-cell Lymphoma</brief_title>
  <acronym>CAR-T</acronym>
  <official_title>Clinical Trial of CD19/CD20 Dual Target CAR-T Cells in the Treatment of Relapsed/Refractory B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>YuLi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen University General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospectively evaluate the safety and effectiveness of CD19/CD20 dual-target CAR-T cells in&#xD;
      the treatment of relapsed/refractory B-cell lymphoma .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospectively evaluate the safety and effectiveness of CD19/CD20 dual-target CAR-T cells in&#xD;
      the treatment of relapsed/refractory B-cell lymphoma . Strictly follow the inclusion criteria&#xD;
      to screen eligible subjects for inclusion in clinical trials. The selected patients received&#xD;
      CD19/CD20 dual-target CAR-T cell therapy. After the treatment is over, follow-up regularly to&#xD;
      determine the survival status and follow-up treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission rate</measure>
    <time_frame>From date of initial treatment to the end of follow up, up to 2 years</time_frame>
    <description>All visible lesions disappeared completely and maintained at least 4 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>From admission to the end of follow up, up to 2 years</time_frame>
    <description>The proportion of surviving patients at the end of the study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lymphoma, B-Cell</condition>
  <condition>Relapse/Recurrence</condition>
  <condition>Refractory Lymphoma</condition>
  <condition>Dual-target CAR-T Cells</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dual target CAR-T cell therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>dual target CAR-T cell therapy</intervention_name>
    <description>CD19/CD20 dual target CAR-T cell therapy</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must meet the following criteria to participate in this study:&#xD;
&#xD;
               1. 14-75 years old, no gender limit;&#xD;
&#xD;
               2. Diagnosed as relapsed/refractory B-cell lymphoma according to the 2020 World&#xD;
                  Health Organization (WHO) diagnostic criteria;&#xD;
&#xD;
               3. ECOG behavior status score is 0-2 points;&#xD;
&#xD;
               4. Expected survival time ≥ 3 months;&#xD;
&#xD;
               5. No contraindications to peripheral apheresis;&#xD;
&#xD;
               6. Flow cytometry/immunohistochemistry confirms that tumor cells express CD20;&#xD;
&#xD;
               7. Those who are tolerant to CD19 CAR-T cell therapy or those with low CD19&#xD;
                  expression;&#xD;
&#xD;
               8. No serious heart, lung, liver or kidney disease;&#xD;
&#xD;
               9. Ability to understand and willing to sign the informed consent form for this&#xD;
                  trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with any of the following cannot be included in this study:&#xD;
&#xD;
               1. Tumor cells do not express CD20;&#xD;
&#xD;
               2. There is active infection;&#xD;
&#xD;
               3. Abnormal liver function (total bilirubin&gt;1.5×ULN, glutamic-pyruvic&#xD;
                  transaminase&gt;2.5×ULN), abnormal renal function (serum creatinine&gt;1.5×ULN);&#xD;
&#xD;
               4. People with unstable angina or New York Heart Association class 3/4 congestive&#xD;
                  heart failure, multiple organ dysfunction;&#xD;
&#xD;
               5. HIV/AIDS patients;&#xD;
&#xD;
               6. Those who need long-term anticoagulation (warfarin or heparin), antiplatelet&#xD;
                  (aspirin, dose&gt;300mg/d; clopidogrel, dose&gt;75mg/d) treatment;&#xD;
&#xD;
               7. Those who received radiotherapy within 4 weeks before the start of the study&#xD;
                  (blood sampling);&#xD;
&#xD;
               8. Known or suspected drug abuse or alcohol dependence;&#xD;
&#xD;
               9. People with mental illness or other conditions cannot obtain informed consent,&#xD;
                  and cannot cooperate with the requirements for completing the experimental&#xD;
                  treatment and inspection procedures;&#xD;
&#xD;
              10. Those who have participated in other clinical trials within 30 days;&#xD;
&#xD;
              11. Pregnant or lactating women, male subjects (or their partners) or female subjects&#xD;
                  have a pregnancy plan during the study period to 6 months after the end of the&#xD;
                  test, and are unwilling to use a medically approved effective contraceptive&#xD;
                  measure during the test period (Such as intrauterine device or condom);&#xD;
&#xD;
              12. The investigator judged that it is not suitable to participate in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Yu, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenzhen University General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>shujiao he, Dr</last_name>
    <phone>+86-0755-21839178</phone>
    <email>he_shujiao@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shenzhen University General hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518055</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shujiao He, Dr</last_name>
      <phone>+86-0755-2183-9178</phone>
      <email>he_shujiao@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>January 23, 2021</last_update_submitted>
  <last_update_submitted_qc>January 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shenzhen University General Hospital</investigator_affiliation>
    <investigator_full_name>YuLi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

